At the October meeting of the MedComms Brunch Club in Oxford, employees of Oxford PharmaGenesis used this year’s Open Access Week as an opportunity to launch the Open Pharma position statement on open access and to present Oxford PharmaGenesis-funded research on open access, clinical trial transparency and the role of professional medical writing support.

Open Pharma is a group that aims to connect pharma with innovations in publishing to achieve a transparent publishing process with accessible outputs. The position statement on open access was launched live via the Open Pharma Twitter page by Dr Chris Winchester, our Chief Executive Officer.

Three Oxford PharmaGenesis-funded research articles that were published this year were presented by Dr Tim Ellison (Senior Medical Writer), Dr Gemma Rogers (Communications Director) and Dr Obaro Evuarherhe (Principal Consultant). Videos of these talks can be seen below and further information can be accessed here.

We would like to thank Peter Llewellyn of NetworkPharma for inviting us to present at this important gathering of medical communications professionals.

Chris WinchesterOpen Pharma: launch of the Open Pharma position statement on open access

Watch Chris launch the Open Pharma position statement on open access and remind us of the importance of open access publishing and research transparency for pharma-funded research, which accounts for approximately half of all medical research.

Recorded 21 October 2019, Oxford, UK.

Tim Ellisonopen access policies of leading medical journals: a cross-sectional study

Tim presents research conducted by employees of Oxford PharmaGenesis on the open access policies of leading medical journals and, particularly, the availability of the gold-standard Creative Commons Attribution (CC BY) open access licence for research articles funded by commercial organizations. This research arose thanks to the authors’ involvement in Open Pharma and it was published in June 2019 by BMJ Open.

Recorded 21 October 2019, Oxford, UK.

Gemma Rogers commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment

How well is the pharmaceutical industry doing when it comes to disclosing the results of clinical trials? Gemma answers this question by summarizing research that evaluated the disclosure of results of clinical trials sponsored by biopharmaceutical companies compared with those that had non-industry funders. This research was co-funded by Shire International GmbH (now part of Takeda) and Oxford PharmaGenesis and it was published by BMJ Evidence Based Medicine in October 2019.

Recorded 21 October 2019, Oxford, UK.

Obaro Evuarherhe professional medical writing support and the quality, ethics and timeliness of clinical trial reporting: a systematic review

Obaro discusses the results of a systematic review that analysed the association between professional medical writing support and the quality, ethics and timeliness of clinical trial reporting. This research was funded by Oxford PharmaGenesis and published in July 2019 by Research Integrity and Peer Review.

Recorded 21 October 2019, Oxford, UK.

Jackie Marchington from Caudex also presented at the Brunch Club, giving an insightful overview of the article ‘Good practice for conference abstracts and presentations: GPCAP’, which was published by Research Integrity and Peer Review in June 2019. A video of her talk can be seen here.